Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition–Related Colitis
- 1 January 2020
- journal article
- letter
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (1) , e15-e20
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitorAbdominal Radiology, 2019
- Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trialsJournal of Cancer Research and Clinical Oncology, 2018
- Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisEuropean Journal of Cancer, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitisCancer Immunology, Immunotherapy, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersJournal of Crohn's and Colitis, 2017
- Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesisOncoImmunology, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014
- The Prevalence and Efficacy of Ganciclovir on Steroid-refractory Ulcerative Colitis With Cytomegalovirus InfectionJournal of Clinical Gastroenterology, 2012